Urothelial Carcinoma: Advances in Immuno-Oncology Host: Jay D. Raman, MD, FACS Co-Hosts: Andrea Apolo, MD and Sima Porten, MD CME Available: auau.auanet.org/node/37325 At the conclusion of this activity, participants will be able to 1. Determine the pros/cons of sequencing strategies with chemotherapy and immunotherapy in first line metastatic urothelial carcinoma. 2. Prioritize treatment options in first line metastatic urothelial carcinoma. 3. Evaluate second line options for metastatic urothelial carcinoma. ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc. Sanofi Genzyme
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
NPR News: 12-08-2025 2AM EST
08 Dec 2025
NPR News Now
NPR News: 12-07-2025 11PM EST
08 Dec 2025
NPR News Now
NPR News: 12-07-2025 10PM EST
08 Dec 2025
NPR News Now
Meidas Health: AAP President Strongly Pushes Back on Hepatitis B Vaccine Changes
08 Dec 2025
The MeidasTouch Podcast
Democrat Bobby Cole Discusses Race for Texas Governor
07 Dec 2025
The MeidasTouch Podcast
Fox News Crashes Out on Air Over Trump’s Rapid Fall
07 Dec 2025
The MeidasTouch Podcast